Guerbet reports net income of 1.3 million euros for the first six months of 2023, down from 3.3 million a year earlier, as well as an adjusted EBITDA margin down from 13.9% to 12.7% year-on-year.

The specialist in contrast products and solutions for medical imaging reported sales of 378.6 million euros, up 2% on a reported basis and 2.8% at constant exchange rates (excluding currency impact).

Guerbet maintains its 2023 objectives of sales growth in excess of 5% on a like-for-like basis and at constant exchange rates, and an adjusted EBITDA margin of around 11%, before returning in 2024 to a level higher than that achieved in 2021 (14.4%).

Copyright (c) 2023 CercleFinance.com. All rights reserved.